Next Article in Journal
3-Amino-5-(indol-3-yl)methylene-4-oxo-2-thioxothiazolidine Derivatives as Antimicrobial Agents: Synthesis, Computational and Biological Evaluation
Next Article in Special Issue
Combined Effect of Caspase-Dependent and Caspase-Independent Apoptosis in the Anticancer Activity of Gold Complexes with Phosphine and Benzimidazole Derivatives
Previous Article in Journal
SAR Analysis of Small Molecules Interfering with Energy-Metabolism in Mycobacterium tuberculosis
Previous Article in Special Issue
Gold Nanoparticles: A New Golden Era in Oncology?
Review

Zinc(II)—The Overlooked Éminence Grise of Chloroquine’s Fight against COVID-19?

1
Faculty of Chemistry, University of Wroclaw, F. Joliot-Curie 14, 50-383 Wroclaw, Poland
2
Screening Laboratory of Biological Activity Tests and Collection of Biological Material, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland
3
Department of Inorganic Chemistry, Faculty of Pharmacy, University of Granada, E-18071 Granada, Spain
4
Department of Physiotherapy, Opole Medical School, Katowicka 68, 40-060 Opole, Poland
*
Author to whom correspondence should be addressed.
Those authors contributed equally.
Pharmaceuticals 2020, 13(9), 228; https://0-doi-org.brum.beds.ac.uk/10.3390/ph13090228
Received: 3 August 2020 / Revised: 28 August 2020 / Accepted: 29 August 2020 / Published: 1 September 2020
(This article belongs to the Special Issue Applications of Medicinal Bioinorganic Chemistry)
Zn(II) is an inhibitor of SARS-CoV-2′s RNA-dependent RNA polymerase, and chloroquine and hydroxychloroquine are Zn(II) ionophores–this statement gives a curious mind a lot to think about. We show results of the first clinical trials on chloroquine (CQ) and hydroxychloroquine (HCQ) in the treatment of COVID-19, as well as earlier reports on the anticoronaviral properties of these two compounds and of Zn(II) itself. Other FDA-approved Zn(II) ionophores are given a decent amount of attention and are thought of as possible COVID-19 therapeutics. View Full-Text
Keywords: COVID-19; SARS-CoV-2; 2019-nCoV; Zn(II) ionophores; chloroquine; hydroxy- chloroquine COVID-19; SARS-CoV-2; 2019-nCoV; Zn(II) ionophores; chloroquine; hydroxy- chloroquine
Show Figures

Graphical abstract

MDPI and ACS Style

Hecel, A.; Ostrowska, M.; Stokowa-Sołtys, K.; Wątły, J.; Dudek, D.; Miller, A.; Potocki, S.; Matera-Witkiewicz, A.; Dominguez-Martin, A.; Kozłowski, H.; Rowińska-Żyrek, M. Zinc(II)—The Overlooked Éminence Grise of Chloroquine’s Fight against COVID-19? Pharmaceuticals 2020, 13, 228. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13090228

AMA Style

Hecel A, Ostrowska M, Stokowa-Sołtys K, Wątły J, Dudek D, Miller A, Potocki S, Matera-Witkiewicz A, Dominguez-Martin A, Kozłowski H, Rowińska-Żyrek M. Zinc(II)—The Overlooked Éminence Grise of Chloroquine’s Fight against COVID-19? Pharmaceuticals. 2020; 13(9):228. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13090228

Chicago/Turabian Style

Hecel, Aleksandra, Małgorzata Ostrowska, Kamila Stokowa-Sołtys, Joanna Wątły, Dorota Dudek, Adriana Miller, Sławomir Potocki, Agnieszka Matera-Witkiewicz, Alicia Dominguez-Martin, Henryk Kozłowski, and Magdalena Rowińska-Żyrek. 2020. "Zinc(II)—The Overlooked Éminence Grise of Chloroquine’s Fight against COVID-19?" Pharmaceuticals 13, no. 9: 228. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13090228

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop